| | | RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute ... |  | Advertisements: |
| 12/06/09 RIDGEFIELD, Conn., Dec. 6 /PRNewswire/ -- Boehringer Ingelheim today announced results from the RE-COVER(TM) study investigating dabigatran etexilate (150 mg BID), a direct thrombin inhibitor (DTI),(2) compared to dose-adjusted warfarin in patients with acute VTE. READ FULL SOURCE |
Back to: Ridgefield WA news
Other newsHot themes this week:
|
| |
| | HOT towns and cities: Northport, WA news • Mead, WA news • Newman Lake, WA news • Oak Harbor, WA news • South Hill, WA news • Dayton, WA news • Roy, WA news • East Side, WA news • Nine Mile Falls, WA news • Maple Valley, WA news • Bryant, WA news • North Seattle, WA news • Green Lake, WA news | |
|
(c) ProvinceCity.com - news and events from small towns, cities and megapolises. All rights reserved. |
| |
Home Sitemap 0 news added |
|
|